 Caladrius Biosciences Inc NASDAQ: CLBS has received 1.4 million in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority. The Program enables qualifying companies to sell a percentage of their New Jersey net operating losses and research and development tax credits to unrelated qualifying corporations. 